Active ingredientPasireotideCat. No. P-P028-001CAS 396091-73-9Family · Pharmaceutical analytical standards
Pasireotide
A somatostatin analogue approved in 2012 in Europe and the United States for Cushing's disease and in 2014 for acromegaly: it curbs the excess hormone production of benign pituitary tumours. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Compared with other somatostatin analogues it has about 40 times higher affinity for receptor type 5, which is abundant on the pituitary cells that produce ACTH.
Go to the active ingredient →Active ingredientPasireotideCat. No. P-P028-001CAS 396091-73-9
Isotopically labelledPasireotide-d7Cat. No. P-P028-002
Active ingredientPasireotide AspartateCat. No. P-P028-003CAS 820232-50-6
ImpurityPasireotide Impurity 1Cat. No. P-P028-004
ImpurityPasireotide Impurity 2Cat. No. P-P028-005
ImpurityPasireotide Impurity 3Cat. No. P-P028-006
ImpurityPasireotide Impurity 4Cat. No. P-P028-007
ImpurityPasireotide Impurity 5Cat. No. P-P028-008
ImpurityPasireotide Impurity 6Cat. No. P-P028-010
ImpurityPasireotide Impurity 7Cat. No. P-P028-011
ImpurityPasireotide Impurity 8Cat. No. P-P028-012
ImpurityPasireotide Impurity 9Cat. No. P-P028-013
ImpurityPasireotide Impurity 10Cat. No. P-P028-014
ImpurityPasireotide Impurity 11Cat. No. P-P028-015
ImpurityPasireotide Impurity 12Cat. No. P-P028-016
ImpurityPasireotide Impurity 13Cat. No. P-P028-017
ImpurityPasireotide Impurity 14Cat. No. P-P028-018No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.